|Description||Targeting New Healthcare Horizons|
|Venture Round, 8/08 |
Zeigler Meditech Equity Partners
Docor International Management
Bargal R&D Investment
|Venture Round, 5/10 |
Ziegler Meditech Equity Partners
AposenseÂ® (formerly NST) is a clinical stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. AposenseÂ® is translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple disease categories, including oncology, cardiology and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.